A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma is a paper indexed in PICO Portal from OpenAlex.
How many citations does A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma have?
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma has 522 citations in the OpenAlex counts PICO Portal stores.
When was A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma published?
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma has 2006 year in the PICO Portal index.
What is the open-access status of A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma?
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma has bronze oa status in the PICO Portal index.
What is the DOI of A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma?
The DOI for A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma is on the source record.
What is the PMID of A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma?
The PMID for A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma is on the source record.
What is the OpenAlex record for A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma?
The OpenAlex for A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma is on the source record.